Profiling Circulating T cells and Tumor Landscape for Predicting Responses to PD-1 blockade in Patients with Non-Small Cell Lung Cancer
Dutta, N. (2024, September 5). https://gupea.ub.gu.se/handle/2077/81804 Immune checkpoint blockade (ICB) has significantly improved outcomes in non-small cell lung cancer (NSCLC), yet only a subset of patients achieves durable responses. This underscores the need for effective methods to assess ICB efficacy. This thesis investigates the response to PD-1 blockade in NSCLC patients across stages I to […]
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
Guan, X., Hu, R., Choi, Y., Srivats, S., Nabet, B. Y., Silva, J., McGinnis, L., Hendricks, R., Nutsch, K., Banta, K. L., Duong, E., Dunkle, A., Chang, P. S., Han, C., Mittman, S., Molden, N., Daggumati, P., Connolly, W., Johnson, M., . . . Patil, N. S. (2024). Anti-TIGIT antibody improves PD-L1 blockade through myeloid […]
Nanomedicine-based co-delivery of a calcium channel inhibitor and a small molecule targeting CD47 for lung cancer immunotherapy
Guo, Y., Bao, Q., Hu, P., & Shi, J. (2023). Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-42972-2 Pro-tumoral macrophages in lung tumors present a significant challenge in immunotherapy. Here, we introduce a pH-responsive nanomedicine approach for activating anti-tumoral macrophages and dendritic cells. Using a layered double hydroxide nanosheet carrier, we co-deliver a T-type calcium channel inhibitor (TTA-Q6) and […]